HAEGT

CAS No. 852155-81-8

HAEGT( —— )

Catalog No. M30080 CAS No. 852155-81-8

HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 425 Get Quote
10MG 608 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    HAEGT
  • Note
    Research use only, not for human use.
  • Brief Description
    HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.
  • Description
    HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.
  • In Vitro
    HAEGT (0-500 μM) is a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV).HAEGT can be catalyzed cleavage by DPP-IV with a km value of 38 μM, Kcat value of 3.1 S-1.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    852155-81-8
  • Formula Weight
    513.5
  • Molecular Formula
    C20H31N7O9
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:His-Ala-Glu-Gly-Thr

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Adomeglivant

    A potent, selective, orally active, small-molecule antagonist of human glucagon receptor with Ki of 6.66 nM.

  • Glucagon-like peptid...

    Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.

  • Orforglipron

    Orforglipron (LY3502970; GLP-1 receptor agonist 1) is an orally available glucagon-like peptide (GLP-1) receptor agonist for the study of obesity and type 1 diabetes in adults.